Zydus Lifesciences Ltd

Zydus Lifesciences Limited conducted its 31st Annual General Meeting (AGM) on August 11, 2026, via video conferencing. The meeting, held from 10:00 a.m. to 11:16 a.m. IST, was attended by the Chairman, Managing Director, several Directors, Key Managerial Personnel, and the Statutory Auditors. The company presented its integrated annual report for the year ended March 31, 2026, highlighting financial performance, ESG initiatives, and commitment to transparency and sustainability. The appointment of Mr. Kulin Lalbhai as an additional independent director was also subject to shareholder approval. Proceedings were recorded and will be available on the company's website.

Zydus Lifesciences announced positive topline results from its completed EVIDENCES-X™ Phase II(b) clinical trial for Saroglitazar Magnesium in patients with Metabolic dysfunction Associated Steatohepatitis (MASH). The trial successfully met its primary endpoint, demonstrating resolution of steatohepatitis with no worsening of fibrosis at 52 weeks, with a treatment difference of 26.5%. The study also showed improvements in key secondary and exploratory endpoints related to liver histology. MASH affects millions globally with limited treatment options. Saroglitazar Mg is already approved in India for MASH and MASLD and is an investigational compound in the US and Europe. These results reinforce the drug's therapeutic potential and Zydus' commitment to chronic liver disease treatments.

Zydus Lifesciences Limited has announced the incorporation of its wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in Gift City, Gandhinagar, Gujarat, effective August 25, 2026. The new entity has an authorized and paid-up share capital of ₹5 Crores. Its primary objective is to function as a Global and/or Regional Corporate Treasury Centre, undertaking treasury activities and services. The incorporation was funded through a 100% cash subscription to the paid-up share capital. As the entity is newly incorporated, it has not yet commenced business operations and therefore has no turnover. This move is part of the company's strategic expansion into treasury operations.

Zydus Lifesciences Ltd has received an improved ESG score of 66 from CRISIL Ratings Limited, up from 61 previously. This score, based on data for the financial year 2025-2026, places the company in the 'strong' category (61-70) according to CRISIL's framework. The company has disclosed this rating in compliance with SEBI regulations.

Zydus Lifesciences Ltd has filed a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing, dated August 21, 2026, pertains to the transmission of 32,577 equity shares. These shares were transferred from the deceased member of the Promoter Group, Late Jasodaben Babubhai Patel, to Mr. Prashant Babubhai Patel, also a member of the Promoter Group. This action is in accordance with Regulation 7(2) of the PIT Regulations, 2015, detailing changes in shareholding within the promoter group due to inheritance.

Zydus Lifesciences Ltd has been assigned an overall ESG rating of 60 by ESGRAIL, a SEBI registered ESG Rating Provider. The rating was prepared independently by ESGRAIL based on publicly available information, and the company did not engage ESGRAIL for this assessment. This disclosure is made in compliance with SEBI regulations.

Zydus Lifesciences Limited has received final approval from the USFDA for its Ascorbic Acid Injection USP. This approval includes 180-days of Competitive Generic Therapy (CGT) exclusivity. The injection is used for the short-term treatment of scurvy when oral administration is not feasible. The product is the generic equivalent of Ascor® Injection and will be manufactured at Zydus' USFDA-approved facility in Gujarat. The brand product had annual sales of approximately USD 11.6 million in the US. Zydus now has 448 approvals and has filed 513 ANDAs with the USFDA.

Zydus Lifesciences Ltd announced key management changes following its Thirty First Annual General Meeting held on August 11, 2026. Shareholders approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five-year term, effective April 1, 2027, to March 31, 2032. Additionally, Mr. Kulin S. Lalbhai has been appointed as an Independent Director for a term of five years, effective May 19, 2026, to May 18, 2031. These decisions were made pursuant to listing regulations and follow an earlier intimation dated May 19, 2026.

Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). Under the agreement, Sentynl gains the exclusive right to commercialize alvelestat in the U.S. upon option exercise, with Mereo leading global development and retaining rest-of-world rights. Mereo will receive an upfront option fee and is eligible for up to $40 million in upfront and R&D payments until NDA filing, plus double-digit tiered royalties on U.S. sales. The companies will collaborate to refine the Phase 3 study design during the option period. Alvelestat is a neutrophil elastase inhibitor targeting a rare genetic respiratory disease affecting an estimated 50,000-80,000 individuals in the U.S. This deal significantly expands Sentynl's rare disease portfolio.

Zydus Lifesciences reported a 22% year-on-year increase in revenue from operations to ₹80,170 million for the first quarter of FY27, ending June 30, 2026. Despite the revenue growth, EBITDA saw an 8% decline to ₹19,294 million, and Net Profit decreased by 36% to ₹9,398 million compared to the previous year. R&D investments stood at 8% of revenues. The company highlighted strong performance in its branded portfolio, which now exceeds 55% of revenues, with significant contributions from the US market. Key business segments like Pharma and Consumer Wellness showed growth, although North America Formulations experienced a slight dip. The company also completed the acquisition of Assertio Holdings, strengthening its US specialty presence.